Advertisement

The January issue of Annals focuses on biologics and asthma

| | January 13, 2025

The January issue of Annals focuses on biologics and asthma

Happy New Year! As the new year begins, it is a great time to peruse another issue of Annals of Allergy, Asthma & Immunology. Must-reads this month include a new Food Allergy Yardstick, as well as an important article providing guidance on the use of CPT codes for allergen immunotherapy – something to be aware of when dealing with payers.

The January issue of Annals focuses on biologics and asthma, and is guest edited by Thomas B. Casale, MD, FACAAI. In fact, the January, February and March issues will feature guest editors. Our CME review article this month examines novel asthma treatments looking beyond the standard step-up therapy. This insightful review explores novel therapies such as inhaled biologics, ultra-long-acting biologics, and inhibitors of Bruton tyrosine kinase and OX-40 ligand, among others. Quickly catch up on the state of the novel asthma therapeutics with this one review.

The response to biologics is examined more closely in two additional reviews. One focuses on the role of biologics in the induction of remission in asthma, while the other review discusses how to identify super-responders – those individuals who are most likely to end up with the most optimal outcomes (likely remission) from their asthma therapy. Our final review this month reminds us of how important the environment is to health. It explores  the effects of plastics on human health with a focus on the impact on allergy and immunology. Not only does this review outline the risks, but it also provides guidance for what the clinician can do to mitigate this risk. As always, review articles in Annals provide you with the knowledge to give your patients the most up-to-date care available.

It’s always good to start the year off with a little chuckle, and this month the Marginal Zone cartootorial examines the effect of biologics on the immune system, as illustrated by a clingy antibody, broken down bicycle, or falling dominoes.

Original research in this month’s Annals examines the impact of opioid use disorder on asthma hospitalizations, the ability of dupilumab treatment to reduce symptoms in patients with chronic sinusitis with nasal polyps, the perspective of allergists on integrating biologics into food allergy care, and the outcomes of intravenous immunoglobulin treatment for respiratory viral infections in immunocompromised patients. Letters explore topics as varied as electronic medication monitoring for severe asthma, evaluation of nonsteroidal anti-inflammatory drug hypersensitivity in pregnant patients, and quality of life in food protein-induced enterocolitis syndrome.

As the new year begins, be sure to make your New Year’s resolution to read Annals every month! The goal of our journal is to provide the most up-to-date information so that you can provide the best possible care to your patients. If you have any comments, please email Annals (annals@ACAAI.org) with any comments about articles and the utility of the journal.

Mitchell H. Grayson, MD, FACAAI
Editor-in-Chief

Annals Logo

Advertisement